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Abstract: Radiation-induced damage is a complex network of interlinked signaling pathways, which
may result in apoptosis, cell cycle arrest, DNA repair, and cancer. The development of thyroid cancer
in response to radiation, from nuclear catastrophes to chemotherapy, has long been an object of study.
A basic overview of the ionizing and non-ionizing radiation effects of the sensitivity of the thyroid
gland on radiation and cancer development has been provided. In this review, we focus our attention
on experiments in cell cultures exposed to ionizing radiation, ultraviolet light, and proton beams.
Studies on the involvement of specific genes, proteins, and lipids are also reported. This review
also describes how lipids are regulated in response to the radiation-induced damage and how they
are involved in thyroid cancer etiology, invasion, and migration and how they can be used as both
diagnostic markers and drug targets.
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1. Introduction
Radiation includes ionizing radiation (IR) and non-IR. IR can be distinguished in photon radiation
(X- and γ-rays) and particle radiation (such as electrons, protons, neutrons, carbon ions, and alpha and
beta particles). IR has enough energy to free electrons from atoms or molecules ionizing them. Non-IR
includes ultraviolet (UV), visible light laser, infrared, microwaves, and radio waves.
It is generally accepted that high acute doses of IR may be harmful to living organisms. In radiation
accidents, the determination of the radiation dose is a key step for medical decisions and patient
prognosis. The estimation of the absorbed dose aids in establishing the risk for acute or chronic
health effects, up to months or years after irradiation [1]. The acute radiation syndrome is caused
by the exposure to high IR during a short period of time, causing depletion of parenchymal cells in
a tissue [2]. Therefore, the doses and duration of radiation exposure are critical for humans. Until
now, radiation is largely used in clinical diagnostics and therapy with remarkable clinical benefits
for patients. Radiotherapy is essentially based on both X- and γ-rays, which provide photons that
are able to specifically penetrate the target and that can be captured on film [3]. Proton therapy
uses proton beams that do not traverse the target but stop at an energy-dependent depth within the
target with no exit dose [3]. Despite positive diagnostic and therapeutic aspects, the inappropriate
use of computed tomography, leading to cancer risk, has been drawing attention for many years [4].
Additionally, the chronic radiation syndrome, ranging from dose-limiting toxicity to the increased
risk of secondary cancers following radiation in patients, should always be considered [5]. To this
end, adaptive responses to low radiation doses have been widely studied both in vitro and in vivo
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to ascertain the biological mechanism of radiation action. Radiation-induced signaling pathways in
different tissues via EGFR, IGFI-R, PI3K, MAPK, JNK, and p38, as well as via FAS-R, TNF-R, and
NFKB, have been reviewed [6].
2. Sensitivity of the Thyroid Gland to Radiation and Cancer Development
Although classically considered resistant to acute effects of radiation [7], the thyroid has actually
proved to be particularly sensitive to the long-term effects of radiation exposure as demonstrated in
studies of human subjects exposed to sublethal radiation doses [8]. More epidemiological studies
were performed. It has been demonstrated by analyzing young adults exposed to radiation during
childhood. A screening study of 11,970 residents of Belarus aged≤18 years at the time of the Chernobyl
nuclear accident showed a risk for neoplastic nodules significantly higher than for non-neoplastic
nodules [9]. High amounts of radiation caused a significant increase in the incidence of thyroid gland
carcinoma, as observed in several nuclear catastrophes such as Hiroshima, Nagasaki, Chernobyl,
and more recently, Fukushima [10]. The effects of radiation in inducing thyroid nodules have been
demonstrated in atomic bomb survivors from 62 to 66 years after exposure during their childhood [11].
The analysis of thyroid consequences of the 2011 Fukushima nuclear reactor accident showed that
35% of the residents developed thyroid nodules and/or cysts [12]. The study of the survivors in
Hiroshima and Nagasaki has demonstrated that the risk for thyroid cancer was significantly higher
if IR exposure occurred at pediatric ages [9]. Exposure to low or moderate doses of IR appeared to
specifically increase the risk of thyroid papillary microcarcinoma, even when exposure occurred during
adulthood [13]. Richardson [14] stated that exposure to IR in adulthood was positively associated with
thyroid cancer among female survivors from atomic bombs (excess relative rate/Gray (Gy) = 0.70;
90% confidence interval = 0.20–1.46), although the risk seemed to be lower if they were exposed to
radiation in their childhood. Ron et al. [15] compared atomic bomb survivors, children treated for tinea
capitis, children irradiated for enlarged tonsils, and infants irradiated for an enlarged thymus gland
with two case controls of untreated patients with cervical cancer and childhood cancer. The authors
reported that the risk to develop thyroid cancer was correlated with age and sex. In fact, in childhood,
the pooled excess relative risk per Gy (ERR/Gy) was 7.7 (95% CI = 2.1, 28.7) and the excess absolute
risk per 10(4) PY Gy (EAR/10(4) PY Gy) was 4.4 (95% CI = 1.9, 10.1); the excess relative risk was greater
(p = 0.07) for females than males. Holm affirmed that, usually, the excess relative risk for thyroid
cancer started 5–10 years after radiation exposure and continued until at least 40 years after exposure;
it was correlated more to the early age (prior to five years of age) than to the sex [16]. Exposure to 131I
during childhood was associated with an increased risk of thyroid cancer and both iodine deficiency
and iodine supplementation appeared to modify such risk [17]. Robbins and Schneider confirmed
the importance of the age, youth being a risk factor. Although the clinical use of radioiodine has not
been reported to cause thyroid cancer, a low number of patients with cancer were young children and
the studied cohorts were too small (consisting of 17 to 191 patients) to provide the statistical power
to detect such a relatively rare event [18]. Among 585 patients with neck radiation, seven survivors
developed papillary thyroid carcinoma (PTC). This indicates that, in adult survivors of cancer during
their childhood or young adulthood with a history of radiation therapy to the neck for cancer, an
annual physical exam should be considered appropriate as a thyroid cancer screening strategy [19].
Patients with head and neck squamous cell carcinoma showed a strong incidence of a subsequent
primary thyroid cancer during the first 5 years after diagnosis and IR-treatment, supporting the concept
that continued surveillance of thyroid status is important in this scenario [20]. Molecular mechanisms
(genes, proteins, and lipids) that played a role in radiation-induced damages were reported in the
following paragraphs.
3. Genes and Proteins Involved in Radiation-Induced Cancer
Advances in biochemistry and molecular biology have allowed the identification of the IR and
non-IR molecular events in the thyroid gland (Figure 1).
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Both IR and UV induced enhanced production of free oxygen radicals and modified pro-oxidant
states [21]. However, the greatest damage to proteins and nucleic acids were with IR.
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3.1. Ionizing Radiations 
IR directly and/or indirectly causes oxidative stresses to the biological systems at the local or 
systematic level by influencing aging, genetic destabilization and mutagenicity, membrane lysis and 
cell death, alteration of enzymatic activities and metabolic events, mitochondrial dysfunction, and 
cancer [22]. The effects of IR in the thyroid gland have been extensively studied. The chronic 
exposure of mature rats to low-intensity γ-rays between 5 and 50 cGy (dose rates: 25, 400 µGy/h) 
induced the formation of micronuclei three times higher in irradiated thyrocytes than in thyrocytes 
of control animals [23]. Furthermore, the residual thyroid of hemi-thyroidectomized rats exposed to 
acute γ-rays with 2–4 Gy presented micronuclei. Ermakova et al. found that the presence of 
micronuclei was also a sensitive indicator of radiation-induced genetic damages in the follicular 
epithelium of thyroid gland [23]. Moreover, IR delayed follicular thyroid cell proliferation [24]. 
Thyroids of old rats irradiated in the neck region with an X-ray single dose of 3 Gy showed an 
increase in proliferating follicular cells two days after irradiation, followed by a phase of sharp 
decrease in cell proliferation between the 2nd and 6th day after irradiation. During the cell 
proliferation phase, the cell cycle was shortened by approximately 50%, predominantly due to a 
decrease of the G1-phase duration [24]. 131I was shown to trigger apoptosis in human thyrocytes [25]. 
The cell viability of human thyroid epithelial cells purified from surgical tissue specimens was not 
affected by single doses of 5 or 50 Gy IR, and there was no induction of Heat shock proteins 
(HSP)-72, as an indicator of acute cellular stress. Nevertheless, the expression of thyroperoxidase 
(TPO), a key enzyme of thyroid hormone synthesis, significantly decreased [26]. The authors 
hypothesized that the suppression of thyroid hormone synthesis due to TPO reduction could 
contribute to an early development of thyroid dysfunction following irradiation, and they 
recommended considering this effect during radiation therapy [26]. On the other hand, the thyroid 
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3.1. Ionizing Radiations
IR directly and/or indirectly causes oxidative stresses to the biological systems at the local or
systematic level by influencing aging, genetic destabilization and mutagenicity, membrane lysis and
cell death, alteration of enzymatic activities and metabolic eve ts, mitochondrial dysfunction, and
cancer [22]. The effects of IR in the thyroid gland have been extensively studied. The chronic exposure
of mature rats to low-intensity γ-rays between 5 and 50 cGy (dose rates: 25, 400 µGy/h) induced
the formation of micronuclei three times higher in irradiated thyrocytes than in thyrocytes of control
animals [23]. Furthermore, the residual thyroid of hemi-thyroidectomized rats exposed to acute γ-rays
with 2–4 Gy presented micronuclei. Ermakova et al. found that the presence of micronuclei was
also a sensitive indicator of radiation-induced genetic damages in the follicular epithelium of thyroid
gland [23]. Moreover, IR delayed follicular thyroid cell proliferation [24]. Thyroids of old rats irradiated
in the neck region with an X-ray single dose of 3 Gy showed an increase in proliferating follicular
cells two days after irradiation, followed by a phase of sharp decrease in cell proliferation between the
2nd and 6th day after irradiation. During the cell proliferation phase, the cell cycle was shortened by
approximately 50%, predo i antly due to a decrease of the G1-phase duration [24]. 131I was shown to
trigger apoptosi in human thyrocytes [25]. The cell viability of human thyroid epithelial ells purified
from surgical tissue specimens was not affected by single doses of 5 or 50 Gy IR, and th re w no
induction of H at shock proteins (HSP)-72, as an indicator of acute cellular stress. Nevertheless, the
expression of thyroperoxidase (TPO), a ke enzyme f th roid hormone synthesis, sig ificantly
decreased [26]. The authors hypothesized that the suppression of thyroid hormone synthesis
due to TPO reduction could contribute to an early development of thyroid dysfunction following
irradiation, and they recommended considering this effect during radiation therapy [26]. On the other
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hand, the thyroid hormone modulation with X-rays induced neoplastic transformation in vitro [27].
Mizuno et al. [28] indicated that IR caused various oncogene activations, with specificity for early gene
alteration uniquely associated with thyroid carcinogenesis. Irradiation of a non-tumorigenic human
thyroid epithelial cell line with α-particles or γ-rays stimulated Exons 6 and 7, as well as p53 mutations
in the childhood PTC in Belarus, presumably as a result of radioiodine fallout [29]. In addition,
IR exposure of cultured human thyroid cells stimulated the induction of c-Jun NH2-terminal kinases
(JNK) activity, not extracellular signal-regulated kinases (ERK) activity, to a 3.5-fold extent. The effect
was specific for thyroid cells as it was absent in fibroblasts [30]. The JNK activation was mediated at
least partially through a protein kinase C (PKC)-dependent pathway [30]. Mitsutake et al. [31] reported
that among PKC-α, β2, δ, ε, and ζ isoforms expressed in primary cultured human thyroid cells, only
PKC-δwas involved in an IR-induced JNK activation. Moreover, PKC-δ acted via mitogen-activated
protein kinase kinase 7 (MAPKK7), not via MAPKK4 [31]. Characteristically, IR was responsible for a
dose-dependent REarranged during Transfection/Papillary Thyroid Cance (RET/PTC) rearrangement
in human thyroid cells [32]. Ameziane et al. [33] demonstrated that this effect was dependent
on generated H2O2 during irradiation; it was responsible for the breaks of double-strand DNA
and facilitated RET/PTC1 formation. As a consequence, by pretreating the cells with catalase,
a scavenger of H2O2, RET/PTC1 rearrangement was decreased. Cells derived from the neural
crest, kidney, and enteric nervous system expressed RET proto-oncogene [34]. Hamatani et al. [35]
reported that in PTC the RET proto-oncogene generated a series of chimeric-transforming oncogenes
collectively described as RET/PTCs. In childhood PTC with a history of radiation exposure, RET/PTC
rearrangements represented a major event and among atomic bomb survivors, the frequency of
rearrangements increased in relation to an increase of radiation dose [35]. In two studies that
employed human fetal thyroid tissue xenografts, Mizuno et al. [28] demonstrated that X-ray irradiation
generated both RET/PTC1 and RET/PTC3 rearrangements, and the RET/PTC1 type was the most
common. Notably, patients exposed to Chernobyl radiation developed PTC, and survivors of the
atomic bomb in Japan had a very high frequency of RET/PTC chromosomal rearrangement [36].
In addiction, B-Raf proto-oncogene (BRAF) mutation (BRAF V600E) was associated with PTC [37].
Guan et al. [38] demonstrated that high iodine intake was a significant risk factor for BRAF V600E
mutation and the development of PTC in the thyroid gland. The prevalence of BRAF V600E mutation
in pediatric PTC was significantly lower than that in adults, 54% versus 85% [39]. On the other hand,
a clinicopathological study showed that BRAF V600E was associated with older age and larger tumor
size [40]. In patients with PTC who were 0–18 years at the time of the Chernobyl accident, BRAF
V600E mutation was present, but the percentage was less than that of RET/PTC1 and RET/PTC3
rearrangements t [41]. Genomic copy number alterations of PTC of the Ukrainian-American cohort
after the Chernobyl accident were associated with BRAF V600E mutation [42]. BRAFV600E mutation
was less frequent in the cases of Hiroshima and Nagasaki survivors exposed to higher radiation
doses [35]. In atomic bomb survivors in Hiroshima, the median radiation dose able to induce PTC
was significantly lower in patients with BRAFV600E mutation than that without the mutation [43].
A screening program of various genetic alterations in children aged 0–18 years old at the time of the
Fukushima accident showed that BRAF V600E was highly prevalent in the 63.2% of the population [44].
The difference of the data in various atomic bomb survivors could be due to the different genetic
profile of patients, considering that the response to radiation of the thyroid gland was dependent on
the genetic profile of the patients [44]. For this reason, Fukushima PTC was completely different from
post-Chernobyl radiation-induced PTC [44], indicating the possibility of non-radiogenic etiology of
PTC. Significant upregulation of a subset of these miRNAs (miR-187, miR-146b, and miR-155) was
found to be more pronounced in PTC carrying RET/PTC rearrangements [45]. The association between
miRNAs and radiation exposure has been reported in a variety of mouse tissues, including spleen,
colon, thymus, and kidney [46]. Acute exposure of thyroid cells to γ-radiation resulted in several
specific patterns of miRNA response not directly associated to carcinogenesis [47].
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3.2. Non-Ionizing Radiations
UV radiation induced apoptosis in the FRTL-5 rat thyroid cell line [48] by the increase of p53 and
caspases 3 and 9, and the decrease of Bcl-2, together with a transient but significant increase in HLA-DR
expression [49] and the impairment of genes involved in thyroid hormone production, such as genes
for thyroglobulin and TPO [50]. The effect was dependent on TSH that stimulates cell proliferation.
Overall, TSH starvation induced virtually all cells to accumulate in the G0/G1 cell cycle phase, blocking
cell proliferation, and rendering cells more resistant to UV-C radiation-induced apoptosis [51]. Thus,
the effect of UV on FRTL-5 cells in culture was strongly related to the physiological state of the
cells. Proliferating cells were more sensitive to radiation treatment than quiescent cells; the cells in a
proapoptotic state caused by the lack of trophic support were less sensitive to radiation treatment [52].
4. Lipids as Regulators of Radiation-Induced Cancer
Differences in the responses to IR and non-IR of proliferating, quiescent and proapoptotic thyroid
cells were associated with a very complex mechanism of lipid metabolism. A specific cross-talk exists
among sphingomyelin (SM), phosphatidylcholine (PC), and phosphatidylinositol (PI) in both cell
membrane and nuclei [53,54] (Figure 2).
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4.1. Ionizing Radiation
After IR-exposure, ceramide and diacylglycerol (DAG) acted as second messengers inducing
proapoptotic and antiapoptotic signals, respectively [55]. FRTL-5 cells submitted to accelerated proton
beams (CERN, Geneva, Switzerland) showed changes of lipid metabolism enzymes [55]. Proton beams
induced quiescent thyroid cells towards a proapoptotic state and proliferating thyroid cells towards an
initial apoptotic state, by altering the nuclear SM-metabolism. In cell nuclei the strong activation of
neutral-sphingomyelinase (N-SMase) reduced SM content that was important for the DNA-stability.
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The ceramide produced in the nucleus probably was translocated to the cytoplasm, where it could be
metabolized to sphingosine and sphingosine-1-phosphate, lipid mediators involved in apoptosis [56].
4.2. Non-Ionizing Radiation
UV radiation enriched the ceramide pool due to acid-sphingomyelinase (A-SMase) and N-SMase
activities and enlarged the DAG pool due to phosphatidylcholine-specific phospholipase C (PC-PLC)
and phosphatidylinositol-specific phospholipase C (PI-PLC) in cell membranes of proliferating
cells [52]. In purified nuclei, radiation stimulated N-SMase and reverse SM-synthase (RSM-synthase)
activities while inhibited PC-PLC, PI-PLC, and SM-synthase activities leading to further ceramide pool
enrichment and DAG pool reduction. The effect of UV irradiation on lipid metabolism was higher in the
nucleus than in cell membranes [52]. The effect on nuclear lipids was very relevant, because of their role
in cell proliferation, differentiation, and apoptosis [57] by acting as a platform for the attachment [58,59]
and regulation [60] of active chromatin and for nuclear drug activity [61,62]. The prolonged presence
in the stratosphere results in exposure to radiation, so stratospheric balloons were used to expose
FRTL-5 cells to radiation present at a 30–40 km altitude for approximately 20 h (BIRBA mission).
In proliferating cells, low doses of stratospheric radiation did not induce cell death but only early
modifications of nuclear SM and PC metabolism. In purified nuclei, SMase and RSM-synthase activities
were increased, whereas PC-PLC and SM-synthase activities were inhibited, leading to an increase
of the ceramide/DAG ratio [63]. These studies indicated that nuclear SM metabolism was involved
in radiation-induced damage (Table 1). The results were relevant considering the possibility that
radiation induced thyroid cancer.
Table 1. The effect of radiation types on nuclear lipid metabolism.
FRTL-5 Nuclei
Radiation Proliferating Cells Quiescent Cells Proapoptotic Cells References
UV
↑ SMase ++ ↑ SMase + ↑ SMase ++
[46]
↑ RSMase ++ ↑ RSMase ++ ↑ RSMase ++
↓ SMsynthase ++ ↓ SMsynthase + ↓ SMsynthase ++
↓ PCPLC ++ ↓ PCPLC + ↓ PCPLC ++
↓ PIPLC ++ ↓ PIPLC + ↓ PIPLC ++
Stratosphere
↑ SMase ++ ↑ SMase +
[57]
↑ RSMase ++ ↑ RSMase ++
↓ SMsynthase ++ ↓ SMsynthase ++
↓ PCPLC ++ ↓ PCPLC +
Protons
↑ SMase +++ ↑ SMase =
[50]↓ SMsynthase = ↓ SMsynthase ++
SMase: sphingomyelinase; RSMase: reverse sphingomyelin-synthase; SMsynthase: sphingomyelin-synthase;
PCPLC: phosphatidylcholine-specific phospholipase C; PIPLC: phosphatidylinositol-specific phospholipase C;
+ low change; ++ medium change; +++ high change. ↑ increased activity; ↓ decreased activity. =: In protons
proliferating cell SMsynthase ↓ should be deleted; in protons quiescent cells SMase ↑ should be deleted.
5. Biomarkers of Thyroid Damage
Considering the molecular effects of radiation on the thyroid gland, the analysis of micronuclei
frequency in peripheral blood lymphocytes is applicable as a biomarker of chromosomal damage,
genome instability, and cancer risk [64]. A negative correlation between micronuclei frequency
and the level of platelets without correlation to thyroid-related hormones has been observed in
blood of patients suffering from differentiated thyroid cancer and treated with radioactive iodine
(131I) [65]. Dom et al. [66] studied children exposed and non-exposed to the Chernobyl radiation and
compared them in the transcriptomes of normal contralateral tissues of PTC; in this way, the authors
identified a gene expression signature (793 probes) that permits discrimination between both cohorts.
To differentiate radiation and no radiation-induced PTC, Port et al. investigated the RNA isolated
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from 11 post-Chernobyl PTCs and 41 sporadic PTCs [67]. The microarray detected 646 upregulated
genes and 677 downregulated genes [67]. The analysis of gene expression can be useful to measure the
predisposition to developing cancer after radiation exposure [68]. In particular, the overexpression
of the CLIP2 gene is the most promising marker; in fact, it was found in the majority of PTCs from
young patients included in the Chernobyl tissue bank [69]. In post-Chernobyl PTC, the expression
of CLIP2 gene was radiation dose-dependent [70]. The use of CLIP2 as radiation biomarker was
supported by a study indicating its involvement in the fundamental carcinogenic processes including
apoptosis, mitogen-activated protein kinase signaling, and genomic instability [71]. In comparison
with normal tissues, thyroid carcinoma tissues from patients had a significant increase in lecithin, SM,
and cholesterol [72]. Changes of the SM content together with other lipids in the blood plasma of
patients with thyroid carcinoma were reported [73]. Serum lipidomic profiling with a panel which
included 36:3phosphatidic acid (PA) and 34:1SM can be useful to distinguish between malignant
thyroid cancer and benign thyroid tumors [74]. Rath et al. found that glycosylation of ceramide could
contribute to the drug-resistance phenotype in thyroid malignancies [75]. Furthermore, it has been
suggested that sphingosine kinase 1 (SphK1) and sphingosine-1-phosphate (S1P) may be relevant in
the etiology of thyroid cancer, and in the regulation of both invasion and migration of thyroid cancer
cells. Therefore, their contents could be useful as specific biomarkers of cancer transformation and
progression [76].
6. Conclusions
To date, a number of specific molecular targets have been identified, by which radiation exerts its
effects upon the thyroid gland, inducing long-term damages including cancer. Many genes, proteins,
and lipids are involved in the mechanism of action, effects, and consequences of radiation, so this
field of study is still widely open. It is becoming increasingly evident in the most recent literature that
specific genes, proteins, and lipids are important targets of both radiation and cancer, but many points
remain obscure. Further studies are required to shed more light on the complexity of interactions
among various cellular components.
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Abbreviations
A-SMase Acid-sphingomyelinase
DAG Diacylglycerol
HLA-DR Human leukocyte antigen-DR
IR Ionizing radiation
JNK c-Jun NH2-terminal kinases
MAPKK7 Mitogen-activated protein kinase kinase 7
N-SMase Neutral-sphingomyelinase
PC Phosphatidylcholine
PC-PLC Phosphatidylcholine-specific phospholipase C
PI Phosphatidylinositol
PI-PLC Phosphatidylinositol-specific phospholipase C
PKC Protein kinase C
PTC Papillary thyroid carcinoma
RET Rearranged during transfection
RSM-synthase Reverse sphingomyelin-synthase
SM Sphingomyelin
SM-synthase Sphingomyelin-synthase
UV Ultraviolet rays
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